Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Promising new candidates include: Amycretin (Novo Nordisk) Orforglipron (Eli Lilly) Survodutide (Boehringer Ingelheim) VK2735 (Viking Therapeutics) MariTide (Amgen) Retatrutide (Eli Lilly) Among the most closely watched candidates is retatrutide, a triple-agonist developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors
Abreu GM2 (1) University of Grande Rio/AFYA, Itabora, RJ, Brasil
Modulation of exogenous glutathione in ultrastructure and photosynthetic performance against Cd stress in the two barley genotypes differing in Cd tolerance
When the pill reaches the stomach, the pH is temporarily raised to prevent the medication from being broken down too quickly
US$ 25.87
US$ 25.59
US$ 26.87
US$ 29.56
US$ 20.72
US$ 27.75
US$ 21.49
